NOVONESIS (NOVOZYMES) B (NZM2.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:NZM2 - DK0060336014 - Common Stock
53.2 EUR
-0.36 (-0.67%)
Overall NZM2 gets a fundamental rating of 5 out of 10. We evaluated NZM2 against 74 industry peers in the Chemicals industry. While NZM2 has a great profitability rating, there are some minor concerns on its financial health. While showing a medium growth rate, NZM2 is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
NZM2 had positive earnings in the past year.
Each year in the past 5 years NZM2 has been profitable.
Each year in the past 5 years NZM2 had a positive operating cash flow.
1.2 Ratios
NZM2 has a Return On Assets of 4.31%. This is in the better half of the industry: NZM2 outperforms 70.27% of its industry peers.
The Return On Equity of NZM2 (6.54%) is better than 64.86% of its industry peers.
NZM2 has a Return On Invested Capital of 5.66%. This is in the better half of the industry: NZM2 outperforms 63.51% of its industry peers.
The Average Return On Invested Capital over the past 3 years for NZM2 is significantly above the industry average of 6.48%.
The 3 year average ROIC (11.83%) for NZM2 is well above the current ROIC(5.66%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.31% | ||
| ROE | 6.54% | ||
| ROIC | 5.66% |
ROA(3y)8.6%
ROA(5y)10.46%
ROE(3y)16.98%
ROE(5y)20.54%
ROIC(3y)11.83%
ROIC(5y)13.54%
1.3 Margins
Looking at the Profit Margin, with a value of 13.61%, NZM2 belongs to the top of the industry, outperforming 93.24% of the companies in the same industry.
In the last couple of years the Profit Margin of NZM2 has declined.
The Operating Margin of NZM2 (21.89%) is better than 94.59% of its industry peers.
NZM2's Operating Margin has declined in the last couple of years.
NZM2's Gross Margin of 52.79% is fine compared to the rest of the industry. NZM2 outperforms 79.73% of its industry peers.
In the last couple of years the Gross Margin of NZM2 has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 21.89% | ||
| PM (TTM) | 13.61% | ||
| GM | 52.79% |
OM growth 3Y-13.18%
OM growth 5Y-7.58%
PM growth 3Y-27.63%
PM growth 5Y-18.32%
GM growth 3Y-6.52%
GM growth 5Y-3.21%
2. Health
2.1 Basic Checks
NZM2 has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
NZM2 has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, NZM2 has more shares outstanding
NZM2 has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 3.93 indicates that NZM2 is not in any danger for bankruptcy at the moment.
NZM2 has a better Altman-Z score (3.93) than 81.08% of its industry peers.
A Debt/Equity ratio of 0.26 indicates that NZM2 is not too dependend on debt financing.
The Debt to Equity ratio of NZM2 (0.26) is better than 66.22% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.93 |
ROIC/WACC0.83
WACC6.79%
2.3 Liquidity
NZM2 has a Current Ratio of 1.61. This is a normal value and indicates that NZM2 is financially healthy and should not expect problems in meeting its short term obligations.
NZM2 has a Current ratio (1.61) which is in line with its industry peers.
A Quick Ratio of 1.00 indicates that NZM2 should not have too much problems paying its short term obligations.
The Quick ratio of NZM2 (1.00) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.61 | ||
| Quick Ratio | 1 |
3. Growth
3.1 Past
NZM2 shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -54.35%.
The earnings per share for NZM2 have been decreasing by -42.95% on average. This is quite bad
The Revenue has grown by 59.91% in the past year. This is a very strong growth!
NZM2 shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -23.23% yearly.
EPS 1Y (TTM)-54.35%
EPS 3Y-23.83%
EPS 5Y-42.95%
EPS Q2Q%N/A
Revenue 1Y (TTM)59.91%
Revenue growth 3Y24.12%
Revenue growth 5Y-23.23%
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 16.99% on average over the next years. This is quite good.
Based on estimates for the next years, NZM2 will show a small growth in Revenue. The Revenue will grow by 7.22% on average per year.
EPS Next Y44.46%
EPS Next 2Y26.15%
EPS Next 3Y20.55%
EPS Next 5Y16.99%
Revenue Next Year5.74%
Revenue Next 2Y6.22%
Revenue Next 3Y6.46%
Revenue Next 5Y7.22%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
NZM2 is valuated quite expensively with a Price/Earnings ratio of 35.23.
NZM2's Price/Earnings ratio is in line with the industry average.
The average S&P500 Price/Earnings ratio is at 26.15. NZM2 is valued slightly more expensive when compared to this.
NZM2 is valuated quite expensively with a Price/Forward Earnings ratio of 25.59.
NZM2's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. NZM2 is more expensive than 64.86% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 36.12. NZM2 is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 35.23 | ||
| Fwd PE | 25.59 |
4.2 Price Multiples
NZM2's Enterprise Value to EBITDA ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 14.37 |
4.3 Compensation for Growth
NZM2's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of NZM2 may justify a higher PE ratio.
NZM2's earnings are expected to grow with 20.55% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.79
PEG (5Y)N/A
EPS Next 2Y26.15%
EPS Next 3Y20.55%
5. Dividend
5.1 Amount
NZM2 has a Yearly Dividend Yield of 1.63%.
Compared to an average industry Dividend Yield of 3.18, NZM2 has a dividend in line with its industry peers.
Compared to the average S&P500 Dividend Yield of 2.41, NZM2 is paying slightly less dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.63% |
5.2 History
The dividend of NZM2 decreases each year by -33.21%.
Dividend Growth(5Y)-33.21%
Div Incr YearsN/A
Div Non Decr YearsN/A
5.3 Sustainability
92.84% of the earnings are spent on dividend by NZM2. This is not a sustainable payout ratio.
DP92.84%
EPS Next 2Y26.15%
EPS Next 3Y20.55%
FRA:NZM2 (11/27/2025, 7:00:00 PM)
53.2
-0.36 (-0.67%)
Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)
Earnings (Next)
Inst Owners45.55%
Inst Owner ChangeN/A
Ins Owners0.01%
Ins Owner ChangeN/A
Market Cap22.05B
Revenue(TTM)5.16B
Net Income(TTM)702.70M
Analysts74.55
Price Target64.14 (20.56%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.63% |
Yearly Dividend0.67
Dividend Growth(5Y)-33.21%
DP92.84%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)29.87%
Min EPS beat(2)14.06%
Max EPS beat(2)45.68%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-1.78%
Min Revenue beat(2)-2.26%
Max Revenue beat(2)-1.31%
Revenue beat(4)2
Avg Revenue beat(4)24.14%
Min Revenue beat(4)-2.26%
Max Revenue beat(4)99.78%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)1.33%
EPS NQ rev (3m)N/A
EPS NY rev (1m)2.38%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)-1.23%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.09%
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 35.23 | ||
| Fwd PE | 25.59 | ||
| P/S | 4.27 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.05 | ||
| P/tB | N/A | ||
| EV/EBITDA | 14.37 |
EPS(TTM)1.51
EY2.84%
EPS(NY)2.08
Fwd EY3.91%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS12.45
BVpS25.92
TBVpS-1.03
PEG (NY)0.79
PEG (5Y)N/A
Graham Number29.67
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.31% | ||
| ROE | 6.54% | ||
| ROCE | 7.49% | ||
| ROIC | 5.66% | ||
| ROICexc | 5.78% | ||
| ROICexgc | 23.66% | ||
| OM | 21.89% | ||
| PM (TTM) | 13.61% | ||
| GM | 52.79% | ||
| FCFM | N/A |
ROA(3y)8.6%
ROA(5y)10.46%
ROE(3y)16.98%
ROE(5y)20.54%
ROIC(3y)11.83%
ROIC(5y)13.54%
ROICexc(3y)18.53%
ROICexc(5y)19.75%
ROICexgc(3y)31.28%
ROICexgc(5y)31.84%
ROCE(3y)15.67%
ROCE(5y)17.93%
ROICexgc growth 3Y-32.98%
ROICexgc growth 5Y-9.18%
ROICexc growth 3Y-47.62%
ROICexc growth 5Y-27.9%
OM growth 3Y-13.18%
OM growth 5Y-7.58%
PM growth 3Y-27.63%
PM growth 5Y-18.32%
GM growth 3Y-6.52%
GM growth 5Y-3.21%
F-ScoreN/A
Asset Turnover0.32
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 1.62 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.61 | ||
| Quick Ratio | 1 | ||
| Altman-Z | 3.93 |
F-ScoreN/A
WACC6.79%
ROIC/WACC0.83
Cap/Depr(3y)134.29%
Cap/Depr(5y)112.94%
Cap/Sales(3y)12.45%
Cap/Sales(5y)10.47%
Profit Quality(3y)105.18%
Profit Quality(5y)105.22%
High Growth Momentum
Growth
EPS 1Y (TTM)-54.35%
EPS 3Y-23.83%
EPS 5Y-42.95%
EPS Q2Q%N/A
EPS Next Y44.46%
EPS Next 2Y26.15%
EPS Next 3Y20.55%
EPS Next 5Y16.99%
Revenue 1Y (TTM)59.91%
Revenue growth 3Y24.12%
Revenue growth 5Y-23.23%
Sales Q2Q%N/A
Revenue Next Year5.74%
Revenue Next 2Y6.22%
Revenue Next 3Y6.46%
Revenue Next 5Y7.22%
EBIT growth 1Y10.22%
EBIT growth 3Y7.76%
EBIT growth 5Y-29.04%
EBIT Next Year67.21%
EBIT Next 3Y25.74%
EBIT Next 5Y18.78%
FCF growth 1Y135.14%
FCF growth 3Y20.37%
FCF growth 5Y-21.39%
OCF growth 1Y83.4%
OCF growth 3Y23.25%
OCF growth 5Y-20.42%
NOVONESIS (NOVOZYMES) B / NZM2.DE FAQ
What is the ChartMill fundamental rating of NOVONESIS (NOVOZYMES) B (NZM2.DE) stock?
ChartMill assigns a fundamental rating of 5 / 10 to NZM2.DE.
What is the valuation status of NOVONESIS (NOVOZYMES) B (NZM2.DE) stock?
ChartMill assigns a valuation rating of 3 / 10 to NOVONESIS (NOVOZYMES) B (NZM2.DE). This can be considered as Overvalued.
What is the profitability of NZM2 stock?
NOVONESIS (NOVOZYMES) B (NZM2.DE) has a profitability rating of 7 / 10.
How financially healthy is NOVONESIS (NOVOZYMES) B?
The financial health rating of NOVONESIS (NOVOZYMES) B (NZM2.DE) is 5 / 10.
Can you provide the expected EPS growth for NZM2 stock?
The Earnings per Share (EPS) of NOVONESIS (NOVOZYMES) B (NZM2.DE) is expected to grow by 44.46% in the next year.